Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AXSM

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.

This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now

This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now

RBC flags this biopharma stock as recession-ready, with stellar upside potential hiding in plain sight.

Investors Beware of These 3 Pharma Stocks

Investors Beware of These 3 Pharma Stocks

Rising costs, regulatory hurdles, and cyberattacks are some of the challenges that the pharmaceutical industry faces. Although the sector looks well-positioned for growth, not all pharma stocks would be able to capitalize on the industry trends. Therefore, investors should look to avoid fundamentally weak pharma stocks: Madrigal Pharmaceuticals (MDGL), Viking…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Better Buy: Axsome Therapeutics vs. Johnson & Johnson

Axsome Therapeutics (AXSM) and Johnson & Johnson (JNJ) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the pharmaceutical sector. But which of these stocks is a better buy now? Read more to find out….

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed.

FDA Issues Complete Response Letter (CRL) to Axsome Therapeutics for AXS-07 In Acute Migraine

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Axsome Therapeutics, Inc. (NASDAQ: AXSM) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.

As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate

The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc's (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval…

inkl

Read news from The Economist, FT, and more,
with one subscription

A Preview Of Axsome Therapeutics's Earnings

A Preview Of Axsome Therapeutics's Earnings

Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Axsome Therapeutics will report an earnings per share (EPS) of $-1.00.

Axsome Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Axsome Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Axsome Therapeutics (NASDAQ:AXSM) will host a conference call at 08:00 AM ET on May 2, 2022, to discuss Q1 2022 earnings results.

Why Axsome Therapeutics Stock Is Trading Higher

Why Axsome Therapeutics Stock Is Trading Higher

Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ).

Axsome Therapeutics: Q4 Earnings Insights

Axsome Therapeutics: Q4 Earnings Insights

Axsome Therapeutics (NASDAQ:AXSM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Organisations

Medical Pharmaceuticals

Medical – Pharmaceuticals

Viking Therapeutics Inc

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play